Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

1 hour ago 1

Maham Fatima

Sat, June 20, 2026 astatine 12:28 PM CDT 1 min read

Precigen Inc. (NASDAQ:PGEN) is 1 of the penny stocks with explosive maturation potential. On June 15, Precigen secured FDA orphan cause exclusivity for PAPZIMEOS, a precision medicine treating big recurrent respiratory papillomatosis/RRP. This regulatory designation prevents the FDA from approving akin treatments for 7 years, extending the drug's marketplace exclusivity and protecting its gross imaginable done August 2032.Developed utilizing Precigen's AdenoVerse platform, PAPZIMEOS uses a modified adenovirus to bid the immune strategy to people HPV 6 and 11, the superior causes of RRP. The treatment, which is presently commercially disposable crossed the US, reduces the request for the predominant surgeries traditionally required to region benign respiratory tumors.

Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Encouraging semipermanent objective information presented astatine the 2026 ASCO Annual Meeting highlighted the treatment's sustained effectiveness. The survey revealed that 83% of implicit responders remained surgery-free for astatine slightest 36 months without further treatments, portion 5 patients required nary further interventions beyond 4 years.Precigen Inc. (NASDAQ:PGEN) is simply a commercial-stage biopharmaceutical institution processing cistron and compartment therapies.While we admit the imaginable of PGEN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey connected Google News.